Accueil   Diary - News   All news CarThera signs a strategic collaboration with Lantheus for its SonoCloud device microbubbles

CarThera signs a strategic collaboration with Lantheus for its SonoCloud device microbubbles

 

US company will extend its microbubble franchise into oncology for French medtech company CarThera - currently running a phase 1/2a study in recurrent glioblastoma with its SonoCloud® system

 


Paris, France, December 9, 2019 – CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces it has entered into a strategic collaboration with US-based company Lantheus. The company will supply microbubbles for use with CarThera’s SonoCloud® device in the treatment of recurrent glioblastoma.

 


CarThera’s SonoCloud device is a proprietary implantable device designed to open the bloodbrain barrier (BBB) using low-intensity pulsed ultrasound (LIPU) and microbubbles. Recurrent glioblastoma (rGBM) is the first clinical indication that could benefit from the SonoCloud. Gliobastoma is a lethal and devastating form of brain cancer with a median survival rate of around 15 months after diagnosis. SonoCloud is intended to facilitate effective delivery of chemotherapy to brain tumors to improve efficacy. CarThera is presently running a pilot (phase 1/2a) study in France and in the United-States (NCT 03744026) and is planning to launch a pivotal study in the upcoming year.

 

 

 

Read the press release